Background Tumour hypoxia is associated with increased metastasis, invasion, poor
therapy response and prognosis. Most PET radiotracers developed and used for clinical …

Background Tissue hypoxia is a pathological condition characterized by reducing oxygen
supply. Hypoxia is a hallmark of tumor environment and is commonly observed in many …

1523 Objectives The aim of our study was to find new imaging tracers to evaluate tumoral
hypoxia with higher contrast and earlier imaging time compared to the commonly used …

Objective Hypoxia is prevalent in tumors and plays a pivotal role in resistance to
chemoradiotherapy. 18F-MISO (18F-labeled fluoromisonidazole) is currently the preferred …

The benefits of PET imaging of tumor hypoxia in patient management has been
demonstrated in many examples and with various tracers over the last years. Although, the …

The study was performed to compare the 18F-labeled nitroimidazole compound
fluoroazomycin arabinoside (18F-FAZA) with the standard hypoxia tracer fluoromisonidazole …

Tumor hypoxia is a major factor responsible for tumor progression, metastasis, invasion, and
treatment resistance, leading to low local tumor control and recurrence after radiotherapy in …

Abstract Introduction Radiolabeled 2-nitroimidazoles (azomycins) are a prominent class of
biomarkers for PET imaging of hypoxia.[18 F] Fluoro-azomycin-α-arabinoside ([18 F] FAZA) …

Background To facilitate hypoxia imaging in a clinical setting, we developed 1-(2, 2-
dihydroxymethyl-3-[18 F]-fluoropropyl)-2-nitroimidazole ([18 F] DiFA) as a new tracer that …

Introduction Hypoxia, a common feature of most solid tumors, is an important predictor of
tumor progression and resistance to radiotherapy. We developed a novel hypoxia imaging …